Managing IP’s Asia-Pacific Special Focus 2022 launched
Managing IP is part of Legal Benchmarking Limited, 4 Bouverie Street, London, EC4Y 8AX
Copyright © Legal Benchmarking Limited and its affiliated companies 2024

Accessibility | Terms of Use | Privacy Policy | Modern Slavery Statement

Managing IP’s Asia-Pacific Special Focus 2022 launched

MIP Asia-Pacific Editorial Image.jpg

Managing IP has partnered with IP leaders from across the Asia-Pacific region to analyse recent court cases and analyse incoming regulations in India, Korea, and Japan

Click here to read the full Asia-Pacific Special Focus 2022.

First, our writers from Anand and Anand explore the significance of a recent ruling concerning trademark protection of film titles and assess the tests used to establish the copyrightability of characters.

In the case Sholay Media Entertainment & Anr. v Yogesh Patel & Ors., the Delhi High Court held that “certain films cross the boundaries of just being ordinary words and the title of the film ‘SHOLAY’ is one of them”. In other words, movie titles are entitled to trademark protection, providing they have achieved a secondary meaning.

Next the authors from FirstLaw P.C. analyse the impact of a ruling from the Supreme Court of Korea on the inventiveness standards for certain inventions, which is encouraging for pharmaceutical patentees.

In 2021, the Court departed from precedent in holding that, to determine the inventiveness of a selection invention, the difficulty to conceive the selection invention should first be examined. If difficulty cannot be shown, the inventiveness of the selection invention may then be assessed based on the existence of a remarkable effect of the selection invention.

In March 2022, the Court went further and upheld the inventiveness of a specific crystalline form invention without requiring corroboration of the presence of a remarkable effect of the crystalline form invention. The approach adopted by the Supreme Court is a promising sign for patentees in Korea, especially those in the pharmaceutical industry.

Finally, our contributor from Shiga International Patent Office (JPO) explains why the Japan Patent Office has introduced restrictions on multi-multi claims, and offers advice to domestic and overseas patent applicants.

The JPO intends to enhance global harmonisation and reduce the burden of examinations and monitoring by third parties. For both overseas and Japanese applicants, it is important to be aware of the regulations and take measures to avoid unnecessary costs and obtain a patent efficiently.

Click here to read the full Asia-Pacific Special Focus 2022.

more from across site and ros bottom lb

More from across our site

The FRAND rate is only 5 cents higher than the per-device rate determined at first instance in 2023
We provide a rundown of Managing IP’s news and analysis from the week, and review what’s been happening elsewhere in IP
Nearly four months after joining Crowell & Moring, Edward Taelman reflects on starting afresh, new clients, and firm culture
Firms discuss the ebb and flow of life sciences IP work and explain how they help professionals pivot between specialities
Mercedes-Benz, Dolby Laboratories, and Panasonic discuss the merits and drawbacks of the USPTO's terminal disclaimer proposal
In-house counsel believe Chinese domestic firms are becoming as sophisticated as international firms, but they may not shift their portfolios just yet
The Court of Appeals for the Federal Circuit is looking to renew a ban that has prevented Judge Pauline Newman from hearing cases
The list of the top representative firms at the UPC may yield few surprises but their success did not come free
The German firms have accounted for 26% of all infringement actions, while US corporations appear interested in litigating at the forum, a report has revealed
Vincent Brault tells us how he fits kitesurfing into his lunchtime routine and why IP is no longer seen as ‘nerdy’
Gift this article